Marshall Wace North America’s Haemonetics HAE Stock Holding History

Marshall Wace North America’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.32M	Sell	32,866 -44,423	-57%	-$2.8M	0.01%	690
2021 Q2	$5.15M	Buy	+77,289	New	+$5.47M	0.02%	539
2020 Q1	–	Sell	-20,671	Closed	-$2.38M	–	1382
2019 Q4	$2.38M	Buy	+20,671	New	+$2.5M	0.01%	539
2019 Q3	–	Sell	-34,646	Closed	-$4.17M	–	1393
2019 Q2	$4.17M	Buy	34,646 +27,787	+405%	+$2.73M	0.03%	403
2019 Q1	$600K	Buy	6,859 +4,419	+181%	+$402K	﹤0.01%	761
2018 Q4	$244K	Buy	+2,440	New	+$256K	﹤0.01%	922
2018 Q3	–	Sell	-172,918	Closed	-$15.5M	–	1090
2018 Q2	$15.5M	Buy	172,918 +48,270	+39%	+$4.08M	0.09%	251
2018 Q1	$9.12M	Sell	124,648 -155,163	-55%	-$10.6M	0.05%	419
2017 Q4	$16.3M	Buy	279,811 +197,942	+242%	+$10.4M	0.09%	269
2017 Q3	$3.68M	Buy	+81,869	New	+$3.4M	0.02%	633
2013 Q3	–	Sell	-12,663	Closed	-$524K	–	650
2013 Q2	$524K	Buy	+12,663	New	+$513K	0.04%	307

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Marshall Wace North America's HAE Position: Q3 2021 in Review

Marshall Wace North America reduced its Haemonetics (HAE) stake by 57% in Q3 2021, selling an estimated $2.8M and leaving 32,866 shares worth $2.32M. The position accounts for 0.01% of the portfolio, ranked #690.

Marshall Wace North America first reported a position in HAE in Q2 2013 and has held it in 11 quarters since. The position peaked at $16.3M in Q4 2017. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

Marshall Wace North America held 32,866 shares of Haemonetics worth $2.32M as of Q3 2021.
Marshall Wace North America sold 44,423 Haemonetics shares in Q3 2021, an estimated $2.8M.
Haemonetics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #690 holding.
Marshall Wace North America first reported a position in Haemonetics in Q2 2013 and has held it in 11 quarters since.
Marshall Wace North America's Haemonetics position peaked at $16.3M in Q4 2017.
245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.